Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene to Pay $162 Million for China Rights to Four Karyopharm Assets

publication date: May 25, 2018

Shanghai's Antengene has licensed China rights to four novel oral drug candidates developed by Karyopharm of Boston in an $162 million agreement.  Karyopharm's candidates, which are based on inhibiting nuclear transport and related targets, are intended mainly for oncology indications. Antegene will pay $12 million upfront and up to $150 million in milestones, plus royalties. It will be responsible for all costs, but will have rights to develop, manufacture and commercialize the four compounds in greater China. More details....

Stock Symbol: (NSDQ: KPTI)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here